Tevimbra (tislelizumab-jsgr) — Medica
Small Bowel Adenocarcinoma
Initial criteria
- age ≥ 18 years
- ONE of: locally unresectable or medically inoperable disease OR advanced or metastatic disease
- ultra-hypermutated phenotype (tumor mutation burden > 50 mutations/megabase)
- ONE of: deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) disease OR polymerase epsilon/delta (POLE/POLD1) mutation positive disease
- used as single agent
- prescribed by or in consultation with an oncologist
Approval duration
1 year